Summary
- Sonnet BioTherapeutics announced plans to launch Hyperliquid Strategies Inc. through a merger.
- The newly established company will focus on Hyperliquid (HYPE) accumulation as its main financial strategy.
- The company expects to hold Hyperliquid and $305,000,000 in cash.
Sonnet BioTherapeutics, a biotechnology company listed on Nasdaq, is set to launch Hyperliquid Strategies Inc., a company for accumulating Hyperliquid (HYPE), through a merger.
According to The Block on the 14th (local time), Sonnet BioTherapeutics announced that it will establish Hyperliquid Strategies Inc. through a merger with the special purpose vehicle (SPV) Rorschach I LLC. The existing company will be incorporated as a subsidiary of the new company.
Hyperliquid Strategies Inc. will make Hyperliquid accumulation its main financial strategy. It is expected to hold 12,600,000 HYPE and $305,000,000 in cash.
Son Min
sonmin@bloomingbit.ioHello I’m Son Min, a journalist at BloomingBit
![[Market] Bitcoin steadies after 'wash shock'…reclaims the $79,000 level](https://media.bloomingbit.io/PROD/news/2d67445a-aa24-46b9-a72d-5d98b73b6aec.webp?w=250)
![[Today’s Key Economic & Crypto Calendar] Atlanta Fed GDPNow, More](https://media.bloomingbit.io/static/news/brief_en.webp?w=250)
![[New York Stock Market Briefing] Rebound on bargain hunting in blue chips…Apple jumps 4%](https://media.bloomingbit.io/PROD/news/3710ded9-1248-489c-ae01-8ba047cfb9a2.webp?w=250)